- MAMMOVISTA B.smart software accelerates workflow for breast image analysis
- teamplay Mammo Dashboard tool helps monitor breast imaging KPIs and optimize workflows
Siemens Healthineers has announced the Food and Drug Administration (FDA) clearance of two new mammography reading and workflow optimization solutions that expand the company’s offerings for breast health. The MAMMOVISTA B.smart reading platform accelerates the reading workflow for breast imaging, and the teamplay Mammo Dashboard tool optimizes workflows through visualization of key performance indicators (KPIs) in the breast imaging process.
Designed with user feedback, MAMMOVISTA B.smart has an intuitive user interface that supports maximum reading performance across multiple imaging modalities and reduces the number of clicks required for specific tasks in addition to increasing image loading speed by up to 75 percent1. Artificial intelligence-supported2 workflows highlight breast tissue abnormalities during the reading phase and provide a confidence score; this score indicates the algorithm’s assessment of the probability of cancerous tissue. Implementing evidence-based AI can help users increase accuracy by up to 10 percent3 and reduce radiologist workloads. Those workloads have increased in recent years due to expanded breast care screening programs and the complexity of multimodality diagnostics.
Operating on the Siemens Healthineers teamplay Digital Health Platform, teamplay Mammo Dashboard offers an intuitive overview of specific institution, modality, and examination KPIs to highlight potential workflow optimizations. Tracked KPIs – including radiation dose, compression, and device utilization – bring transparency to key steps of the mammography examination process while identifying possible bottlenecks. With this information, institutions can increase workflow efficiency and standardization in imaging.
“MAMMOVISTA B.smart and teamplay Mammo Dashboard are powerful additions to the holistic breast health portfolio of Siemens Healthineers, which covers every step along a woman’s breast health journey,” said Niral Patel, Vice President of X-ray Products at Siemens Healthineers North America. “These latest offerings optimize radiologist workflow and can help healthcare institutions standardize their fleet of mammography systems, supporting the larger goal of optimizing breast cancer care for every woman.”
1 Data on file
2 AI is an option and available with Transpara® powered by FusionAI™, ScreenPointMedical.
3 FDA wide-angle DBT reader study with Transpara, clearance number K193229
For further information on MAMMOMVISTA B.smart, please see
Contact for journalists
Jeff Bell
Phone: +484-868-8346; E-mail: jeffrey.t.bell@siemens-healthineers.com
Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) pioneers breakthroughs in healthcare. For everyone. Everywhere. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers and its regional companies is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care. In fiscal 2021, which ended on September 30, 2021, Siemens Healthineers, which has approximately 66,000 employees worldwide, generated revenue of €18.0 billion and adjusted EBIT of €3.1 billion. Further information is available at www.siemens-healthineers.com.
